The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research (ICR). We bring together researchers across these institutions from different disciplines to develop innovative ways to address challenges in cancer research and improve patient outcomes.
We’re inviting applications for our latest round of the Development Fund seed funding scheme. Find out more about the aims of the fund, eligibility and how to apply.
Exploiting a Hidden Weakness in MYC-Driven Cancers
Although MYC deregulation occurs in more than 50% of cancers and is associated with aggressive disease, MYC has long been considered “undruggable”. Researchers from Imperial College London, the Francis Crick Institute, and the Institute of Cancer Research (ICR), in a study co-authored by one of our Centre-funded PhD student James Zhang, found that MYC-deregulated cancers are highly sensitive to NMT inhibitors, presenting a possible new avenue to target a range of difficult to treat cancers.
2025 Development Fund Awardees
Five diverse projects were awarded funding from our 2025 Development Fund, selected by our Research Subcommittee for their innovation, potential patient impact, focus on convergence science, and use of cross-institutional expertise.
e1c13180-2779-4153-a215-a2b954a0b764.png?sfvrsn=31d52f92_3)